1. Home
  2. FRD vs ARMP Comparison

FRD vs ARMP Comparison

Compare FRD & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Friedman Industries Inc.

FRD

Friedman Industries Inc.

HOLD

Current Price

$35.37

Market Cap

134.3M

Sector

Industrials

ML Signal

HOLD

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

HOLD

Current Price

$4.68

Market Cap

156.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRD
ARMP
Founded
1965
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.3M
156.4M
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
FRD
ARMP
Price
$35.37
$4.68
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
73.2K
157.0K
Earning Date
06-11-2026
05-07-2026
Dividend Yield
0.79%
N/A
EPS Growth
N/A
N/A
EPS
1.46
N/A
Revenue
$121,157,278.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$23.33
N/A
Revenue Growth
55.82
N/A
52 Week Low
$15.10
$2.36
52 Week High
$39.07
$14.98

Technical Indicators

Market Signals
Indicator
FRD
ARMP
Relative Strength Index (RSI) 53.75 47.69
Support Level $30.68 $4.81
Resistance Level $37.08 $5.50
Average True Range (ATR) 2.31 0.54
MACD -0.32 0.15
Stochastic Oscillator 44.34 79.70

Price Performance

Historical Comparison
FRD
ARMP

About FRD Friedman Industries Inc.

Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

Share on Social Networks: